Heart failure & cardiomyopathies
Effect of Dapagliflozin on Accelerometer-Based Measures of Physical Activity in Patients With Heart Failure: An Analysis of the DETERMINE Trials
Authors' conclusion
In this exploratory analysis of the DETERMINE trials, dapagliflozin had a beneficial effect on selected accelerometer-based measures of physical activity in patients with heart failure across the entire left ventricular ejection fraction spectrum, yet did not improve 6-minute walk distance, as previously reported.
Study context
- Population
- Patients with HF across the entire LVEF spectrumof 817 randomised with adequate data
- Participants
- 211 patients
- Comparison
- Dapagliflozin vs placebo
- Primary endpoint
- Change in accelerometer outcomes: total steps, time in light-to-vigorous and moderate-to-vigorous physical activity, movement intensity during walking, vector magnitude units, total activity counts
- Follow-up
- Baseline to week 16
Methodological detailsvoluntary substudy, exploratory analysis
- Voluntary substudy
- Exploratory analysis
Primary result
As reported in the abstract
Mean change from baseline in accelerometer measures · 16 weeks
DapagliflozinBetween-group difference (95% CI)
Number of steps
778(240–1315)
DapagliflozinBetween-group difference, hours (95% CI)
Time in moderate-to-vigorous physical activity
0.16(0.03–0.29)
DapagliflozinBetween-group difference, counts per minute (95% CI)
Mean vector magnitude units
25(0.1–49)
Per minute, as printed
Original publication
Effect of Dapagliflozin on Accelerometer-Based Measures of Physical Activity in Patients With Heart Failure: An Analysis of the DETERMINE Trials. Circ Heart Fail. Published 30 August 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →